Buprenorphine is a potent analgesic agent, it has been shown to be as effective as morphine. The main clinical application of buprenorphine is to relief postoperative pains or for patients in the terminal phase of cancer. The chance of becoming addiction and abuse is low, therefore it is pretty safe for clinical use. The half life of buprenorphine is short, since its hepatic extraction (extraction ratio is 0.7 to 0.9) and metabolism are high. For these reasons, oral administration of buprenorphine becomes impractical due to the need of giving drug frequiently. The present invention is related to enhancers used in transdermal preparations of narcotic analgesic agents. This invention employs pure components of Chinese herbs in a fixed ratio as transdermal penetration enhancers. Compositions of these transdermal preparations usually include 0.1 to 50% of narcotic analgesic agent, 0.1 to 70% of pure components from Chinese herb as transdermal penetration enhancers, and other necessary excipients for transdermal delivery. Studies for the present invention in nude mice revealed that a transdermal preparation containing 10% of terpineol can delivery 15 mg of buprenorphine through 10 cm.sup.2 skin area in 48 hours, which satisfied the need of practical use.

National Science Council

Transdermal delivery of buprenorphine preparations

Natural and synthetic compounds having a lactone structure methods for alleviation of pain, especially pain associated with disorders such as melanoma, leukemia, breast cancer, lung cancer, ovarian cancer, colon cancer, esophagus cancer, liver cancer, and lymphatic cancer. Initial studies have shown that patients can be taken off of morphine when the preferred alpha-methylene-gamma-butyrolactone is administered in a dosage of between 60 and 120 mg/day intramuscularly.

Gomez; Federico M.

Gomez Garcia-Godoy; C. Federico

Magnachem International Laboratories, Inc.

Synthetic lactone formulations and method of use

The present application relates to a compound of formula (I) ##STR00001## The present application also relates to synthesizing the compound of formula I and treating a patient with the compound of formula I having a neuropsychiatric illnesses such as a depressive disorder, schizophrenia; alcohol, nicotine, and morphine withdrawal induced depression and hyperalgesia; neuropathic pain caused by anticancerous drugs; diabetic neuropathic pain; obsessive compulsive disorder; alcohol withdrawal syndrome; static and dynamic allodynia in diabetic and cancer patients on anticancer therapy and chronic pain therapy.

morphine/cancro

Transdermal delivery of buprenorphine preparations

Synthetic lactone formulations and method of use

Synthetic lactone formulations and method of use

Coumarinyl-thiazole-sulfonyl conjugate and preparation thereof

Il database di erbe medicinali più completo supportato dalla scienza